Generic & generic-plus pharmaceuticals under development (dossiers for out-licensing)
Development Pipeline: Generics Under Development
- Dossiers for out licensing
Loading…
Anfarm Hellas S.A.
GreeceFounded 1967Healthcare ManufacturerAccredited by several National Health Authorities worldwideEU Falsified Medicines Directive serialization: Commission Delegated Regulation (EU) 2016/161EU GMP Manufacturing License (Greek National Organization for Medicines / EOF)
Freeze-dried (lyophilized) sterile powders for injection and infusion: Anfarm's flagship platform with 40 million vials/year capacity across 10 freeze dryers and 4 dedicated production lines.
Sterile β-lactam antibiotic powders (cephalosporins and carbapenems) filled in a separate, dedicated Beta building. 15 million vials/year (~20 tons of API) across multi-filling volumes.
Conventional non-sterile pharmaceuticals (tablets, capsules, oral solutions, syrups, creams and nasal sprays), with automated tableting, coating and encapsulation and bottle/blister packaging.
Anfarm's R&D pipeline of generic and generic-plus products with dossiers available for out-licensing: spanning next-generation antibiotics, antifungals, GLP-1 analogues and CNS agents with published dossier-availability timelines.
Liquid sterile products for injection and infusion: manufactured aseptically in class A/B environments or via terminal sterilization, including sterile plastic bags. 450 m² production area.